Works matching IS 1082801X AND DT 2007 AND VI 42 AND IP 8

Results: 54

FDA advisory panel votes to keep rosiglitazone on market, but not without caveats.

Published in:

2007

By:

Kuznar W

Publication type:

Journal Article

Debate about rosiglitazone safety prompts hearing in House; FDA seeks to update clinical research policies.

Published in:

2007

By:

Wechsler J

Publication type:

Journal Article

Nebivolol demonstrates neutral effect on glucose levels.

Published in:: 2007
Publication type:: Journal Article

Sumatriptan plus naproxen reduces traditional and nontraditional migraine symptoms.

Published in:: 2007
Publication type:: Journal Article

Pulmonary effects of inhaled insulin are small, reversible.

Published in:: 2007
Publication type:: Journal Article

Exenatide associated with sustained blood glucose control, weight loss after 3 years of treatment.

Published in:: 2007
Publication type:: Journal Article

Quick-release bromocriptine has favorable cardiovascular safety profile [corrected] [published erratum appears in FORMULARY 2007 Oct;42(10):501].

Published in:: 2007
Publication type:: Journal Article

Lipid-lowering therapies reduce development of peripheral neuropathy.

Published in:: 2007
Publication type:: Journal Article

PROactive: pioglitazone improves CV outcomes in patients with renal dysfunction, type 2 diabetes, and macrovascular disease.

Published in:: 2007
Publication type:: Journal Article

Researchers debate the CV safety of rosiglitazone.

Published in:: 2007
Publication type:: Journal Article

SOLAR: initial rosuvastatin superior to atorvastatin, simvastatin for reaching LDL-C goals in high-risk patients.

Published in:: 2007
Publication type:: Journal Article

Patients with cancer and ACS, with or without thrombocytopenia, may benefit from use of aspirin.

Published in:: 2007
Publication type:: Journal Article

Lamotrigine, valproate emerge as superior epilepsy treatment options as assessed in SANAD trial.

Published in:: 2007
Publication type:: Journal Article

Bare-metal and drug-eluting stents yield similar cardiac event risks, according to pooled analysis.

Published in:: 2007
Publication type:: Journal Article

LOCSS trial: once-daily fluticasone plus salmeterol superior to montelukast as step-down therapy for mild persistent asthma.

Published in:: 2007
Publication type:: Journal Article

Budesonide plus formoterol associated with better control of persistent asthma control than gold standard therapy.

Published in:: 2007
Publication type:: Journal Article

HORIZON: yearly infusion of zoledronic acid reduces risk of fracture in postmenopausal women with osteoporosis.

Published in:: 2007
Publication type:: Journal Article

ADAPT: Naproxen and celecoxib demonstrated to be ineffective In primary prevention of AD.

Published in:: 2007
Publication type:: Journal Article

Drug and formulary trends.

Published in:: 2007
Publication type:: Journal Article

Vernakalant.

Published in:

2007

By:

Dia EQ;
Rathbun RA;
Song JC

Publication type:

Journal Article

Dr von Eschenbach's vision: FDA's newest commissioner faces multiple challenges.

Published in:

2007

By:

Wechsler J

Publication type:

Journal Article

DAD study: use of protease inhibitors increases risk of myocardial infarction.

Published in:: 2007
Publication type:: Journal Article

Interim analysis of RECORD trial provides inconclusive data regarding cardiovascular safety of rosiglitazone.

Published in:: 2007
Publication type:: Journal Article

Acute pain and migraine/headache.

Published in:: Formulary, 2007, v. 42, n. 8, p. 512
Publication type:: Article

FDA advisory panel votes to keep rosiglitazone on market, but not without caveats.

Published in:

Formulary, 2007, v. 42, n. 8, p. 510

By:

Kuznar, Wayne

Publication type:

Article

Debate about rosiglitazone safety prompts hearing in House; FDA seeks to update clinical research policies.

Published in:: Formulary, 2007, v. 42, n. 8, p. 505
Publication type:: Article

Sumatriptan plus naproxen reduces traditional and nontraditional migraine symptoms.

Published in:: Formulary, 2007, v. 42, n. 8, p. 504
Publication type:: Article

Nebivolol demonstrates neutral effect on glucose levels.

Published in:: Formulary, 2007, v. 42, n. 8, p. 504
Publication type:: Article

Exenatide associated with sustained blood glucose control, weight loss after 3 years of treatment.

Published in:: Formulary, 2007, v. 42, n. 8, p. 503
Publication type:: Article

Pulmonary effects of inhaled insulin are small, reversible.

Published in:: Formulary, 2007, v. 42, n. 8, p. 502
Publication type:: Article

Quick-release bromocriptine has favorable cardiovascular safety profile.

Published in:: Formulary, 2007, v. 42, n. 8, p. 501
Publication type:: Article

Lipid-lowering therapies reduce development of peripheral neuropathy.

Published in:: Formulary, 2007, v. 42, n. 8, p. 498
Publication type:: Article

PROactive: Pioglitazone improves CV outcomes in patients with renal dysfunction, type 2 diabetes, and macrovascular disease.

Published in:: Formulary, 2007, v. 42, n. 8, p. 497
Publication type:: Article

Researchers debate the CV safety of rosiglitazone.

Published in:: 2007
Publication type:: Proceeding

SOLAR: Initial rosuvastatin superior to atorvastatin, simvastatin for reaching LDL-C goals in high-risk patients.

Published in:: Formulary, 2007, v. 42, n. 8, p. 496
Publication type:: Article

Patients with cancer and ACS, with or without thrombocytopenia, may benefit from use of aspirin.

Published in:: Formulary, 2007, v. 42, n. 8, p. 494
Publication type:: Article

Lamotrigine, vaiproate emerge as superior epilepsy treatment options as assessed in SANAD trial.

Published in:: Formulary, 2007, v. 42, n. 8, p. 494
Publication type:: Article

Bare-metal and drug-eluting stents yield similar cardiac event risks, according to pooled analysis.

Published in:: Formulary, 2007, v. 42, n. 8, p. 493
Publication type:: Article

LOCSS trial: Once-daily fluticasone plus salmeterol superior to montelukast as step-down therapy for mild persistent asthma.

Published in:: Formulary, 2007, v. 42, n. 8, p. 490
Publication type:: Article

Budesonide plus formoterol associated with better control of persistent asthma control than gold standard therapy.

Published in:: Formulary, 2007, v. 42, n. 8, p. 490
Publication type:: Article

ADAPT: Naproxen and celecoxib demonstrated to be ineffective In primary prevention of AD.

Published in:: Formulary, 2007, v. 42, n. 8, p. 488
Publication type:: Article

HORIZON: Yearly infusion of zoledronic acid reduces risk of fracture in postmenopausal women with osteoporosis.

Published in:: Formulary, 2007, v. 42, n. 8, p. 488
Publication type:: Article

Vernakalant.

Published in:

Formulary, 2007, v. 42, n. 8, p. 475

By:

Dia, Ederlyn Q.;
Rathbun, Robert A.;
Song, Jessica C.

Publication type:

Article

Drug and Formulary Trends.

Published in:: Formulary, 2007, v. 42, n. 8, p. 472
Publication type:: Article

Dr von Eschenbach's vision: FDA's newest commissioner faces multiple challenges.

Published in:

Formulary, 2007, v. 42, n. 8, p. 467

By:

Wechsler, Jill

Publication type:

Article

Safety labeling updates & new warnings.

Published in:: Formulary, 2007, v. 42, n. 8, p. 466
Publication type:: Article

DAD study: Use of protease inhibitors increases risk of myocardial infarction.

Published in:: Formulary, 2007, v. 42, n. 8, p. 465
Publication type:: Article

Interim analysis of RECORD trial provides inconclusive data regarding cardiovascular safety of rosiglitazone.

Published in:: Formulary, 2007, v. 42, n. 8, p. 465
Publication type:: Article

FDA actions in brief.

Published in:: Formulary, 2007, v. 42, n. 8, p. 464
Publication type:: Article

First-time generic approvals.

Published in:: Formulary, 2007, v. 42, n. 8, p. 463
Publication type:: Article